Verona Pharma’s ensifentrine meets COPD objectives
Therapy shows quality of life boost and significant improvement in lung function
Read More
Tag: ensifentrine
Verona’s ensifentrine meets primary endpoint
Chronic obstructive pulmonary disease phase 3 study shows statistically significant improvements in lung function
Read More
Verona Pharma’s ensifentrine heads for phase 3 chronic obstructive pulmonary disease trial
The company completes its enrolment in phase 3 trial evaluating ensifentrine for treatment of COPD
Read More
Verona completes enrolment in pilot study of potential COVID-19 inhaler
Ensinfentrine is a first-in-class inhaled inhibitor of the enzymes phosphodiesterase 3 and 4
Read More
Verona Pharma launches late-stage COPD trial programme
Phase III trial programme will evaluate nebulised ensifentrine in moderate-to-severe COPD
Read More
Verona begins pilot study of potential COVID-19 inhaler
Inhaled ensifentrine will be assessed in hospitalised patients
Read More
Verona progresses PhII trial of COPD inhaler
Following a pause because of coronavirus, the company has now kicked off the second part of a trial assessing a pressurised metered-dose inhaler formulation of ensifentrine
Read More
Verona publishes Phase II COPD results
Ensifentrine showed clinically and statistically significant improvements in lung function at all doses.
Read More
Verona Pharma share positive ensifentrine results in COPD
The trial consisted of 37 patients with moderate-to-severe COPD, who received a single dose of either the drug or a placebo.
Read More
Another EU patent for Verona in COPD drug
The patent further strengthens Verona Pharma’s intellectual property estate.
Read More
Verona announces positive results from Phase II COPD trial
Verona Pharma’s COPD inhaler has shown positive results in a Phase II study.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
